Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute

Ursula Matulonis, M.D., Dana-Farber Cancer Institute

Caption: Ursula Matulonis, M.D., and colleagues say the technique used to identify a new subtype of ovarian cancer may prove useful in determining how a patient's cancer might respond to a specific treatments.

Credit: Sam Ogden

Usage Restrictions: None

Related news release: New subtype of ovarian cancer may be vulnerable to anti-angiogenic drugs